Trinity Biotech has unveiled CGM+, its advanced continuous glucose monitoring (CGM) system designed to integrate multi-sensor data and real-time analytics.
The advanced CGM solution targets the $260bn AI wearables market and aims to cater to the evolving demands of AI-powered healthcare and wellness.
Positioned as an AI-native platform, CGM+ is in the final stages of device development, promising a new era in intelligent wearables.
Unlike conventional CGMs, CGM+ offers more than glucose monitoring.
It features an ultra-thin, minimally invasive electrochemical glucose sensor that continuously tracks heart activity, body temperature, and physical activity.
The comprehensive data stream is optimised for real-time AI analysis, providing a deeper understanding of metabolic and physiological health.
Trinity Biotech CEO John Gillard said: “CGM+ is not just a device, it’s a proprietary data engine we are building for the AI health ecosystem.
“We believe this technology can power the next wave of personalised, predictive, and preventative care, while opening up entirely new commercial pathways for Trinity Biotech, from device sales to AI-driven data services.
“It will also position us to compete well beyond traditional diagnostics, at the intersection of chronic disease management, digital health and consumer wellness.”
Trinity Biotech aims to merge medical-grade monitoring with consumer wellness insights through the new CGM+ platform.
Its unique needle-free glucose sensor technology reduces disposable components and waste, significantly lowering care costs compared to current market leaders.
The advanced design not only enhances efficiency but also supports the company’s commitment to sustainable healthcare solutions.
The CGM+ platform is set to play an important role in AI-based diagnostics, behavioural coaching, and chronic disease management.
The platform is engineered to support both clinical and consumer applications, bridging the gap between medical-grade monitoring and everyday health optimisation.
It is expected to offer a differentiated solution for both clinical and consumer health markets, marking a significant advancement in the AI wearables sector.
Trinity Biotech plans to commercially launch CGM+ by mid-2026, which is expected to open multiple revenue streams.
The revenue streams include device sales, AI analytics subscriptions, and partnerships with healthcare providers, insurers, and digital health platforms.
Furthermore, the company recently completed a pre-pivotal trial of its upgraded glucose sensor technology and expects to issue key findings from this trial shortly.
Gillard added: “CGM+ is the cornerstone of our vision for AI-native health monitoring.
“We’re not just adding a product—we’re building a scalable platform with recurring revenue potential that we believe can drive long-term growth across clinical and consumer markets.”
